부산대학교 도서관

Gynecologic cancer treatments have evolved significantly. Several targeted therapies are approved for use in combination with cytotoxic therapy, as monotherapy or as maintenance therapy following first- or second-line treatment. These new agents compel the need to educate the medical community on the management of “new” side effects. This review provides medical teams who care for patients with gynecologic malignancies, a succinct compilation of reported adverse events (AEs) and their management strategies when using targeted therapy. New for gynecologic cancers are immune checkpoint inhibitors related AEs such as endocrinopathies and colitis. Ocular AEs with tissue factor-directed antibody–drug conjugates (ADCs), as well as a plethora of AEs encountered with use of anti-angiogenic, poly(ADP)ribose polymerase (PARP) inhibitors, mitogen-activated protein kinase (MEK) inhibitors, and other tyrosine kinase receptor inhibitors. Oncologists, hospitalists, and emergency department teams and outpatient providers may benefit from a convenient reference source of commonly reported AEs of targeted agents with strategies for early diagnosis, management recommendations, and dose modifications. New therapies in gynecologic cancers have introduced lesser-known side effects. This review compiles AEs data with their reported management strategies. Clinicians/oncologists from community to emergency will benefit from this resource.